[Clinical experience with ambroxol syrup (author's transl)].
In an open trial trans-4-[(2-amino-3,5-dibromo-benzyl)-amino]-cyclohexanol hydrochloride (ambroxol, NA 872) in the form of ambroxol syrup was given to non-hospitalised patients suffering from acute and chronic bronchitis. A marked reduction in coughing and dyspnoea as well as an improvement in expectoration was apparent. The maximum effect was reached on the third day of treatment. The effect can be maintained by consistent prolongation of the therapy. There were no side effects.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000551:Ambroxol / Q000008:administration & dosage / Q000627:therapeutic use*; D001964:Bromhexine / Q000031:analogs & derivatives*; D001991:Bronchitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012996:Solutions; D013997:Time Factors
D012996:Solutions; D000551:Ambroxol; D001964:Bromhexine
Klinische Erfahrungen mit Ambroxol-Saft.